- Trials with a EudraCT protocol (131)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
131 result(s) found for: Organ systems.
Displaying page 1 of 7.
EudraCT Number: 2012-005159-18 | Sponsor Protocol Number: CRO2047 | Start Date*: 2013-08-28 | ||||||||||||||||
Sponsor Name:Imperial College, London | ||||||||||||||||||
Full Title: An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS) | ||||||||||||||||||
Medical condition: Septic shock. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-002547-94 | Sponsor Protocol Number: 2011-420 | Start Date*: 2013-03-25 | ||||||||||||||||
Sponsor Name:Dept. of Intensive Care 4131, Rigshospitalet | ||||||||||||||||||
Full Title: Early Goal-Directed Nutrition in ICU Patients – EAT-ICU Trial | ||||||||||||||||||
Medical condition: Acutely admitted, mechanically ventilated intensive care unit patients. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-006782-83 | Sponsor Protocol Number: EC08/00230 | Start Date*: 2013-09-24 |
Sponsor Name:Hospital Universitario Virgen de las Nieves | ||
Full Title: Prevention MODS by modulating the inflammatory response through melatonin administration in surgical patients with severe sepsis. | ||
Medical condition: Septic patients of abdominal surgery | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-004856-35 | Sponsor Protocol Number: DHTCA_P09889 | Start Date*: 2008-03-17 | ||||||||||||||||||||||||||
Sponsor Name:Imperial College London | ||||||||||||||||||||||||||||
Full Title: Scavenging free haemoglobin atenuates the systemic inflmmatory response following surgery | ||||||||||||||||||||||||||||
Medical condition: Systemic inflammatory response and associated multiorgan failure that follows cardiopulmonary bypass for cardiac surgery | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-002255-10 | Sponsor Protocol Number: IRMINEpilot | Start Date*: 2016-06-30 | ||||||||||||||||||||||||||
Sponsor Name:Abertawe Bro Morgannwg University Health Board | ||||||||||||||||||||||||||||
Full Title: INFLAMMATORY RESPONSE IN MAJOR INJURY & RECOMBINANT HUMAN ERYTHROPOIETIN (IRMINE) - A PILOT STUDY | ||||||||||||||||||||||||||||
Medical condition: Post-trauma multiple organ failure: a manifestation of the systemic inflammatory/immune response to major injuries. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000899-25 | Sponsor Protocol Number: FP1CLI006 | Start Date*: 2016-12-16 | |||||||||||
Sponsor Name:Faron Pharmaceuticals Ltd | |||||||||||||
Full Title: A Phase II Double-blind, Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Fail... | |||||||||||||
Medical condition: Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Prematurely Ended) EE (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000410-30 | Sponsor Protocol Number: EstrogenPOP2 | Start Date*: 2016-12-01 |
Sponsor Name:Medical University of Vienna, Department of Obstetrics and Gynecology | ||
Full Title: PREOPERATIVE LOCALLY APPLIED OESTROGEN IN POSTMENOPAUSAL WOMEN WITH PELVIC ORGAN PROLAPSE: CHANGES IN SUBJECTIVE AND OBJECTIVE OUTCOME: A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ST... | ||
Medical condition: Pelvic organ prolapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000097-19 | Sponsor Protocol Number: TRANCHE | Start Date*: 2016-06-10 |
Sponsor Name:Charité Universitätsmedizin Berlin | ||
Full Title: Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinje... | ||
Medical condition: Food allergy | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003406-27 | Sponsor Protocol Number: SL0043 | Start Date*: 2020-10-14 | |||||||||||
Sponsor Name:UCB Biopharma SRL | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) PL (Completed) DE (Completed) BG (Completed) HU (Completed) ES (Completed) AT (Completed) GR (Completed) PT (Prematurely Ended) GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) IT (Completed) DK (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005659-19 | Sponsor Protocol Number: RG_14-287 | Start Date*: 2015-10-21 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A phase II study of the use of azacitidine for the treatment of patients with chronic graft-versus-host-disease who have failed therapy with corticosteroids | |||||||||||||
Medical condition: Chronic Graft versus Host Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018383-16 | Sponsor Protocol Number: C33457/2047 | Start Date*: 2010-09-17 | |||||||||||
Sponsor Name:Cephalon, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of CEP-33457 in Patients With Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Patients With Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) ES (Completed) CZ (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000179-18 | Sponsor Protocol Number: RG_13-322 | Start Date*: 2015-04-28 |
Sponsor Name:University of Birmingham [...] | ||
Full Title: Local Oestrogen Treatment in Postmenopausal Women Undergoing Pelvic Organ Prolapse Surgery (LOTUS) - Feasibility Study | ||
Medical condition: Pelvic organ prolapse | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002112-99 | Sponsor Protocol Number: F1K-MC-EVDK | Start Date*: 2006-09-26 | |||||||||||
Sponsor Name:Eli Lilly & Company Limited | |||||||||||||
Full Title: A Phase 2 Study to Evaluate Dose and Duration of Treatment of Drotrecogin Alfa (Activated) Using Serial Measurements of Protein C in Patients with Severe Sepsis and Multiple Organ Dysfunction | |||||||||||||
Medical condition: severe sepsis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) SE (Prematurely Ended) FR (Completed) FI (Completed) IT (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002761-19 | Sponsor Protocol Number: OP201 | Start Date*: 2019-10-21 | |||||||||||
Sponsor Name:Oncopeptides AB | |||||||||||||
Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy | |||||||||||||
Medical condition: Patients with AL Amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004139-29 | Sponsor Protocol Number: RETIC | Start Date*: 2011-12-06 | |||||||||||
Sponsor Name:Medizinische Universität Innsbruck / UK für Anästhesie und Intensivmedizin & UK für Allgem. u. Chirurg. Intensivmedizin | |||||||||||||
Full Title: RETIC trial: Reversal of Trauma Induced Coagulopathy by using Coagulation factor concentrates or Fresh frozen Plasma | |||||||||||||
Medical condition: Major trauma (Injury Severity Score, ISS >15), clinical signs/risk of blood loss and coagulopathy as measured by rotational thrombelastometry (ROTEM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004113-85 | Sponsor Protocol Number: PA101-SM-02 | Start Date*: 2015-04-16 | |||||||||||
Sponsor Name:Patara Pharma, LLC | |||||||||||||
Full Title: Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study with PA101 in Patients with Indolent Systemic Mastocytosis | |||||||||||||
Medical condition: Indolent Systemic Mastocytosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022780-35 | Sponsor Protocol Number: 10-005 | Start Date*: 2011-07-06 | |||||||||||
Sponsor Name:THERAKOS, Inc. | |||||||||||||
Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD) | |||||||||||||
Medical condition: Chronic graft-versus-host disease (cGvHD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002290-22 | Sponsor Protocol Number: 308801 | Start Date*: 2005-01-19 |
Sponsor Name:Schering AG | ||
Full Title: Phase II open-label study to investigate the efficacy and safety of PTK787/ZK222584 orally administered once daily or twice daily at a total daily dose of 1250 mg as second-line monotherapy in pati... | ||
Medical condition: Non-Small Cell Lung Cancer (NSCLC) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002904-14 | Sponsor Protocol Number: C14101 | Start Date*: 2019-06-03 |
Sponsor Name:Pharming Technologies B.V. | ||
Full Title: A Phase I/II, Open Label, Proof of Concept Study to investigate Tolerability and Safety of Treatment with Recombinant Human C1 Inhibitor in Patients with Preeclampsia. | ||
Medical condition: Preeclampsia | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002093-23 | Sponsor Protocol Number: 1.01 | Start Date*: 2011-09-21 |
Sponsor Name:University of Tartu | ||
Full Title: Bioavailability of oral N-acetylcysteine in different intensive care unit patient groups | ||
Medical condition: Severe neurotrauma, severe pulmonary infections and severe gastrointestinal disease (eg peritonitis, pancreatitis, ileus, major abdominal surgery etc). Need for liquefaction of viscous sputum | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: EE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
